NIS793 is another anti-TGF-β antibody that is being tested in a phase I/Ib clinical trial in patients with different solid tumors (breast, lung, HCC, colorectal, pancreatic and renal) NCT02947165. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.